183065-68-1

Usage

Chemical Properties

Off-white Cryst

Upstream product

• 124-38-9 carbon dioxide 
• 461-96-1 3,5-difluorobromobenzene 
• 537013-51-7 4-bromo-2,6-difluorobenzaldehyde 
• 651027-04-2 (3,5-dibromo-2,6-difluorophenyl)triethylsilane 
• 651027-05-3 (3,4-dibromo-2,6-difluorophenyl)triethylsilane 
• 184910-37-0 (4-bromo-2,6-difluorophenyl)triethylsilane 
• 651027-03-1 (3-bromo-2,6-difluorophenyl)triethylsilane 
• 651027-02-0 1-triethylsilyl-2,6-difluorobenzene 

Downstream Products

• 162744-59-4 (4-bromo-2,6-difluoro-phenyl)methanol 
• 840481-49-4 4-bromo-2,6-difluorobenzamide 
• 773134-11-5 4-bromo-2,6-difluorobenzoic acid methyl ester 
• 1008119-07-0 C₁₃H₁₅BF₂O₄ 
• 1223424-77-8 3-{4-[4-(2,4-dimethylphenyl)piperazine-1-carbonyl]-3,5-difluorophenyl}oxazolidin-2-one 
• 1223431-18-2 (4-bromo-2,6-difluorophenyl)[4-(2,4-dimethylphenyl)piperazin-1-yl]methanone 
• 1223432-29-8 (4-bromo-2,6-difluorophenyl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone 
• 1264616-16-1 C₁₁H₁₂BF₂NO₃ 
• 1448719-04-7 (S)-2-(4-cyano-2,6-difluorobenzoylamino)-3-[4-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)phenyl]propionic acid propyl ester 
• 1448719-05-8 (S)-2-(4-aminomethyl-2,6-difluorobenzoylamino)-3-[4-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)phenyl]propionic acid propyl ester 
• 957346-35-9 methyl 4-bromo-2-fluoro-6-nitromethylbenzoate 
• 957346-37-1 5-bromo-7-fluoro-2,3-dihydro-1H-isoindol-1-one 
• 1569023-16-0 C₉H₉BrFNO₂ 
• 1526200-39-4 5-(4-bromo-2,6-difluorophenyl)-1,3,4-thiadiazol-2-amine 

Relevant academic research and scientific papers

Liquid crystal compound containing dimethylbenzene and difluoromethylenedioxy linking group and application thereof

The invention discloses a liquid crystal compound containing a dimethylbenzene and difluoromethyleneoxy linking group and application of the liquid crystal compound. The compound is as shown in formula I. In the molecular structure of the compound as show

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

A 2,6-difluoro-4-bromophenylacetic formyl chloride method for the preparation of (by machine translation)

The invention discloses a 2, the 6 [...] difluoro -4 the method for preparing [...] bromophenylacetic formyl chloride, relates to the technical field of organic synthesis, to 3, the 5 two fluoro bromobenzene [...], diisopropylamine, composite material, ca

NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC

The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.

HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES

The present invention provides compounds useful as C-met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of C-met kinase mediated diseases or disorders with them.

5-ALKYNYL-PYRIMIDINES

The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

MODULATORS OF DOPAMINE NEUROTRANSMISSION

The present invention relates to novel1-(4H-1,3-benzodioxin-2-yl)methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically asdopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

INHIBITORS OF STEAROYL-COA DESATURASE

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.